Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px
Document › Details

Biotest AG. (5/24/16). "Press Release: Biotest Opens New Plasma Collection Centre in Brookings, South Dakota, USA. 12 Plasma Collection Centres in Europe – 19 in the US to Ensure Long-term Plasma Supply". Dreieich.

Organisations Organisation Biotest Pharmaceuticals Corporation
  Group Creat (Group)
  Organisation 2 Biotest AG
  Group Creat (Group)
Products Product blood plasma
  Product 2 plasma protein (human)
Person Person Carlisle, Ileana (Biotest 201605 CEO of Biotest Pharmaceuticals Corp)
     


Biotest Pharmaceuticals Corporation, Boca Raton, USA (BPC), a 100% subsidiary of Biotest AG, Germany, a leading manufacturer of plasma proteins and biological products, is pleased to announce the addition of its newest plasma collection centre located at Brookings, South Dakota, USA. The state-of-the-art facility officially opened its doors for business on May 24, 2016 and brings the total number of BPC's plasma collection centres to 19.

"This facility is one of the four plasma centres BPC plans to open in 2016, reinforcing our continued commitment to the expansion of our existing network of plasma collection centres. We are fully committed to better serve the thousands of patients worldwide who rely on plasma-based therapies", said Ileana Carlisle, BPC's Chief Executive Officer.

BPC has invested approximately EUR1.8 million in the construction of this facility. The Company expects to add over 40 jobs to the Brookings local economy and currently has employment opportunities available for medical personnel and phlebotomists.


About human blood plasma

Human blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest is one of the world's six largest manufacturers of plasma protein products.


About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,300 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.


IR contact

Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact

Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.de


Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany www.biotest.de

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, Munich, Stuttgart


Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

   
Record changed: 2016-05-25

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Creat (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px




» top